Pages
Products
mCherry Lentivirus

mCherry Lentivirus

Cat.No. :  LV00952Z

Titer: ≥1*10^7 TU/mL / ≥1*10^8 TU/mL / ≥1*10^9 TU/mL Size: 100 ul/500 ul/1 mL

Storage:  -80℃ Shipping:  Frozen on dry ice

Inquire for Price

Lentivirus Particle Information

Quality Control

Cat. No. LV00952Z
Description This lentivirus contains mCherry under the control of CMV promoter and puromycin selection marker under the control of PGK promoter.
Target Gene mCherry
Titer Varies lot by lot, for example, ≥1*10^7 TU/mL, ≥1*10^8 TU/mL, ≥1*10^9 TU/mL etc.
Size Varies lot by lot, for example, 100 ul, 500 ul, 1 mL etc.
Storage Store at -80℃. Avoid multiple freeze/thaw cycles.
Shipping Frozen on dry ice
Creative Biogene ensures high-quality lentivirus particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between lentivirus particle lots.
Mycoplasma Creative Biogene routinely tests for mycoplasma contamination using a mycoplasma detection kit. Cell lines are maintained for approximately 20 passages before being discarded and replaced with a new vial of early passage cells. Approximately 2 weeks after thawing, cell culture supernatants are tested for mycoplasma contamination. Creative Biogene ensures that lentiviral products are free of mycoplasma contamination.
Purity Creative Biogene evaluates the level of impurities, such as residual host cell DNA or proteins, in prepared lentiviral vectors to ensure they meet quality standards.
Sterility The lentiviral samples were inoculated into cell culture medium for about 5 days and the growth of bacteria and fungi was tested. Creative Biogene ensures that the lentiviral products are free of microbial contamination.
Transducibility Upon requirement, Creative Biogene can perform in vitro or in vivo transduction assays to evaluate the ability of lentivirus to deliver genetic material into target cells, and assess gene expression and functional activities.
Proviral Identity Confirmation All Creative Biogene lentiviral vectors are confirmed to have correctly integrated provirus using PCR. This test involves transducing cells with serial dilutions of the lentiviral vector, harvesting the cells a few days later, and isolating genomic DNA. This DNA is then used as a template to amplify a portion of the expected lentiviral insert.
Quick Inquiry

Background

Case Study

Publications

Q & A

Customer Reviews

Two types of cancer vaccines using lentiviral vectors have been investigated: dendritic cell vaccines and cancer cell vaccines. Dendritic cells loaded with tumor antigen peptides can be used as a vaccine against cancers that express that antigen. Sipuleucel-T is one such dendritic cell vaccine that has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of prostate cancer. Lentiviral vectors have been investigated as a way to express tumor antigens in dendritic cells or to modify co-stimulatory signals to further enhance their efficacy. Lentiviral vectors have also been used to constitutively activate the MAP kinase pathway in dendritic cells, thereby enhancing anti-tumor responses in mice. Another vaccine approach is to use cancer cells that already express the tumor antigen of interest, rather than dendritic cells that must be loaded with peptides. A study with B-cell lymphoma cells lentivirally transduced with co-stimulatory proteins and interleukin-12 showed that using these modified cells as a vaccine enhanced the immunogenicity of the parental lymphoma cell line in a mouse model. Lentiviral vectors have also been used to transform the K562 erythroleukemia cell line into artificial antigen-presenting cells for in vitro T-cell expansion and potentially for in vivo immunization, similar to the previously reported GVAX vaccine. Although more research is needed to determine the clinical efficacy and safety of cancer vaccines developed using lentiviral vectors, these approaches may bring new treatment options to patients.

Selective neuronal vulnerability in neurodegenerative diseases remains poorly defined. Using the ATXN1[82Q] model of spinocerebellar ataxia type 1 (SCA1), researchers explored the hypothesis that regional differences in Purkinje neuron degeneration might provide new insights into selective vulnerability. Researchers found that ATXN1[82Q] Purkinje neurons in the anterior cerebellum degenerated earlier than neurons in the tubercular region, and this early degeneration was associated with selective dysregulation of ion channel transcripts and altered Purkinje neuron firing. To understand the basis for the selective dysregulation of channel transcripts, researchers identified a modest increase in expression of the ATXN1 corepressor Capicua (Cic) in Purkinje neurons in the anterior cerebellum. Importantly, disruption of the association between ATXN1 and Cic rescued levels of these ion channel transcripts, whereas lentiviral overexpression of Cic in the nodular zone accelerated aberrant Purkinje neuron firing and neurodegeneration. These findings reinforce the central role of Cic in the cerebellar pathophysiology of SCA1 and suggest that only modest reductions in Cic could have profound therapeutic impacts in SCA1.

To investigate the causal relationship between regional differences in Cic expression and ion channel dysregulation, researchers used lentiviral vectors to increase Cic expression in the nodular zone. When Cic lentivirus was co-injected with mCherry lentivirus, mCherry expression was reliably overexpressed in the posterior half of lobule IX within the tubercle region (Figure 1A), so patch clamp recordings were performed on Purkinje neurons in this region. At 10 days post-injection, a significant fraction of Purkinje neurons from lobule IX were found to display irregular spikes or depolarization blocks in ATXN1[82Q] mice injected with Cic lentivirus (Figure 1B and C). Cic-dependent disruption of Purkinje neuron pacemaking was associated with a decrease in AHP (Figure 1D). These findings suggest that increased Cic levels render ATXN1[82Q] Purkinje neurons hyperexcitable. Furthermore, ATXN1[82Q] mice injected with Cic lentivirus showed accelerated Purkinje neuron degeneration in the tubercle region 70 days after injection (Figure 1E and F). These data demonstrate that only modestly greater expression of Cic and Cic-dependent hyperexcitability are likely to be responsible for accelerated degeneration of anterior cerebellar Purkinje neurons in ATXN1[82Q] mice.

Figure 1. Increased Cic expression results in Purkinje neuron hyperexcitability and accelerates Purkinje neuron degeneration.Figure 1. Increased Cic expression results in Purkinje neuron hyperexcitability and accelerates Purkinje neuron degeneration. (Chopra R, et al., 2020)

Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Customer Reviews
Lot-to-lot consistency

The lot-to-lot consistency of Creative Biogene's mCherry Lentivirus ensures reproducibility across experiments, which is crucial for our long-term research projects.

Canada

08/05/2020

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Needs improvement

Satisfaction

General satisfaction

Very satisfaction

CBpromise

Our promise to you:
Guaranteed product quality, expert customer support.

24x7 CUSTOMER SERVICE
CONTACT US TO ORDER